Technology Development

NIAID Collaborative Research Opportunities

On this page:

• Autoimmune Disorders
• Biodefense
• Cancer
• Dengue
• Hepatitis
• HIV/AIDS
• Infectious Diseases
• Malaria
• Other
• Sexually Transmitted Infections—Non-HIV/AIDS

Autoimmune Disorders

• Ribosomal Protein S3 (PRS3), an Essential Component of NF-kappaB, Is a Novel and Selective Drug Target
• Cell Based Immunotherapy
• Muramyl Dipeptide as a Therapeutic Agent for Inflammation
• Treatment and Prevention of Inflammatory Bowel Disease (IBD) Using Mutant and Chimeric IL-13 Molecules
• Mouse Model of Individual Unresponsive to Interferon
• Treatment of Inflammatory Bowel Disease (IBD) Using NF-KB Decoy Polynucleotides
• A Method of Treating Inflammatory Bowel Disease (IBD)
• Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors  

Biodefense

• Monodisperse and Modified Yersinia pestis Capsula F1-V Antigen Fusion Proteins for Vaccination Against Bubonic and Pneumonic Plague
• Improved Bacterial Host for Production of Anthrax Toxin Proteins and Vaccines: Bacillus anthracis BH450
• Monoclonal Antibodies Against Orthopoxviruses
• Monoclonal Antibodies That Neutralize B. anthracis Protective Antigen (PA), Lethal Factor (LF), and Edema Factor (EF) 

Cancer

• Human Cancer Therapy Using Engineered Anthrax Lethal Toxin
• Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms
• Treatment of Primary Tumors and Tumor Metastases With TNF-alpha Antagonists
• Novel Method of Treating Cancer Using Ixolaris

Dengue

• Development of Antigenic Chimeric St. Louis Encephalitis Virus/Dengue Virus Type Four Recombinant Viruses (SLEV/DEN4) as Vaccine Candidates for the Prevention of Disease Caused by SLEV
• Monoclonal Antibodies That Bind or Neutralize Dengue Virus
• Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses
• Development of Dengue Virus Type 3 Vaccine Candidates Containing Either 1) Nucleotide Deletions in the 3'-UTR of the Genome Consisting of More Than 30 Contiguous Nucleotides in One or More Multiple Regions, or 2) a 3'-UTR Derived From DEN4 and Containing the delta30 Nucleotide Deletion
• Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4 

Hepatitis

• Swine Hepatitis E Virus Available for Use in Diagnosis, Prevention, and Treatment of Hepatitis E       
• Major Neutralization Site of Hepatitis E Virus and Use of This Neutralization Site in Methods of Vaccination
• A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry 

HIV/AIDS

• CC Chemokine Receptor 5 DNA, New Animal Models, and Therapeutic Agents for HIV Infection
• Inhibiting HIV Infection Using Integrin Antagonists
• Adoptive Immunotherapy for Reestablishing HIV-Specific Cytotoxic T-Cell (CD8 T-Cell) Function in HIV and AIDS Patients and Methods for Assessing the Reestablishment of CD8 T-Cell Function
• A Novel Chimeric Protein for Prevention and Treatment of HIV Infection
• Mouse Model of Individual Unresponsive to Interferon

Infectious Diseases

• Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation
• Human-Bovine Chimeric Respiratory Syncytial Virus (RSV) Vaccines
• Targeting Poly-Gamma-Glutamic Acid To Treat Staphylococcus epidermis and Related Infections
• A Varicella-Zoster Virus Mutant That Is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics
• Discovery of Novel Pharmacophores Inhibiting the Growth of Mycobacterium tuberculosis
• Mouse Model of Individual Unresponsive to Interferon
• North-2'-Deoxy-Methanocarbathymidines as Antiviral Agents Against Poxviruses
• Live Attenuated Virus Vaccines for La Crosse Virus and Other Bunyaviridae
• Live Attenuated Vaccine To Prevent Disease Caused by West Nile Virus
• Humanized Monoclonal Antibodies That Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use

Malaria

• Anti-Plasmodium Compositions and Methods of Use
• Chondroitin Sulphate A Binding Domains: Potential Vaccine for Malaria
• A Novel Treatment for Malarial Infections

Other

• A Rapid Ultrasensitive Assay for Detecting Prions Based on the Seeded Polymerization of Recombinant Normal Prion Protein (rPrP-sen)
• Microwave-Assisted Freeze Substitution of Biological and Biomedical Samples (MWFS)
• A Universal Antigen Delivery Platform for Enhanced Immune Response 
• Regulation of ATG7 Beclin 1 Program of Autophagic Cell Death by Caspase-8
• Identification of Candidate Ligands Which Modulate Antigen Presenting Cells
• Collagen-Induced Platelet Aggregation Inhibitor From Mosquitor Salivary Glands
• Method of Promoting Hematopoietic Stem Cell Engraftment by Enhancement of CXCR4 Activity
• Sialostatin Mediation Controls Blood-Feeding Success of the Tick Ixodes scapularis
• Insect Salivary Proteins as Potent Adjuvants for Enhancing Immune Responses
• A Newly Discovered Bacterium in the Family Acetobacteraceae
• Mouse Monoclonal Antibodies to MAD1, a Human Spindle Assembly Checkpoint Protein for Maintaining Chromosomal Segregation

Sexually Transmitted Infections—Non-HIV/AIDS

• Chlamydia Vaccine
• Use of Mono-Amine Oxidase Inhibitors To Prevent Herpes Virus Infections and Reactivation From Latency
• Identification of a Fusion/Entry Receptor for Human Herpesvirus-8

back to top